TrialThe Lancet. Oncology2017

Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial.

Corinne Faivre-Finn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.